Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

NCT02933489 · View on ClinicalTrials.gov ↗

Study Summary

This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense breasts. Abbreviated breast MRI is a low cost procedure in which radio waves and a powerful magnet linked to a computer and used to create detailed pictures of the breast in less than 10 minutes. These pictures can show the difference between normal and diseased tissue. Digital tomosynthesis mammography is a procedure that uses multiple x-rays pictures of each breast to produce a 3-dimensional rendering of the entire breast. Combined screening with abbreviated breast MRI and digital tomosynthesis mammography may be a better method to screen women with dense breasts.

Conditions Studied

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • DIAGNOSTIC_TEST Contrast-enhanced Magnetic Resonance Imaging
  • DIAGNOSTIC_TEST Digital Tomosynthesis Mammography

Study Locations (20)

Illinois

  • Northwestern University — Chicago
  • University of Chicago Comprehensive Cancer Center — Chicago
  • NorthShore University HealthSystem-Evanston Hospital — Evanston
  • Clinical Radiologists SC — Springfield

Florida

  • Boca Raton Regional Hospital — Boca Raton
  • Mayo Clinic in Florida — Jacksonville
  • Diagnostic Center for Women LLC — Miami

Colorado

  • The Women's Imaging Center — Denver
  • Radiology Imaging Associates — Englewood

Indiana

  • Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis
  • The Community Hospital — Munster

Kansas

  • University of Kansas Cancer Center — Kansas City
  • University of Kansas Hospital-Westwood Cancer Center — Westwood

Arizona

  • Banner MD Anderson Cancer Center — Gilbert

California

  • Huntington Memorial Hospital — Pasadena

Connecticut

  • Norwalk Hospital — Norwalk

Trial Details

FieldValue
Enrollment Target 1,516 participants
Start Date 2016-12-27
Est. Completion 2026-12-31
Phase NA

Sponsor

ECOG-ACRIN Cancer Research Group

52 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02933489

The ClinicalTrials.gov registry entry for NCT02933489 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,516 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 52 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Asymptomatic appearing as the primary indexed condition, and to 4 interventions — of which Quality-of-Life Assessment is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02933489 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Illinois, Florida, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02933489 about?

NCT02933489 is a clinical study titled "Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts". This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense breasts. Abbreviated breast MRI is a low cost procedure in which radio waves and a powerful magnet linked to a comput...

What is the current status of trial NCT02933489?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,516 participants. The study started on 2016-12-27. Estimated completion is 2026-12-31.

What conditions does trial NCT02933489 study?

This clinical trial studies the following conditions: Asymptomatic. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02933489?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Contrast-enhanced Magnetic Resonance Imaging (DIAGNOSTIC_TEST), Digital Tomosynthesis Mammography (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02933489?

This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 52 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02933489 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial